REGULATORY

• MHLW Eyes More Convenient Sakigake Scheme with Legislation, Criteria Won't Change: Official
  September 10, 2019

• Evenity Ordered to Warn of CV Event Risks in Revised Label
  September 9, 2019

• MHLW to Launch 5th Round of Sakigake Invitations on Oct. 1
  September 9, 2019

• MHLW Loathe to Disclose Probe Documents on Clinical Research Bill Leak
  September 6, 2019

• In Fight against AMR, Japan Set to Forge Prefectural Networks to Push Proper Antibiotic Use
  September 5, 2019

• Senior Bureaucrat Chided for Leaking Draft Clinical Research Bill
  September 4, 2019

• Japan, Vietnam Regulators to Hold 1st Joint Symposium Next Month
  September 4, 2019

• Japan Drug Production Up 2.8% to 6.9 Trillion Yen in 2018: MHLW
  September 2, 2019

• MHLW’s Health Policy Bureau Requests Increased Budget for Core Hospitals, Centers for Pediatric and Rare Diseases
  September 2, 2019

• MEXT Requests 103.4 Billion Yen to Fuel Healthcare R&D in FY2020
  September 2, 2019

• METI Seeks 5.1 Billion Yen in FY2020 to Develop Technology Platforms for Cell and Gene Therapies
  September 2, 2019

• Astellas’ “Post-Nesp” Renal Anemia Drug Now in Line for September Approval, 1st Forteo Biosimilar Too
  August 30, 2019

• MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug
  August 30, 2019

• Ultomiris Caught by CEA Rule despite Intractable Disease Indication: Chuikyo
  August 29, 2019

• Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
  August 29, 2019

• MHLW Seeks Record 32.6 Trillion Yen Budget for FY2020
  August 28, 2019

• Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
  August 28, 2019

• Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
  August 28, 2019

• Public Knowledge-Based Filing OK’ed for Busulfex Use in Lymphoma HSCT
  August 27, 2019

• Evenity under PMDA Risk Review
  August 27, 2019

ページ

• « 先頭
• ‹ Prev
• …
• 195
• 196
• 197
• 198
• 199
• 200
• 201
• 202
• 203
• …
• Next ›
• 最終 »